Effect of laminar air flow and building construction on aspergillosis in acute leukemia patients: A retrospective cohort study by Iwasaki, Makoto et al.
Title
Effect of laminar air flow and building construction on
aspergillosis in acute leukemia patients: A retrospective cohort
study
Author(s)
Iwasaki, Makoto; Kanda, Junya; Hishizawa, Masakatsu;
Kitano, Toshiyuki; Kondo, Tadakazu; Yamashita, Kouhei;
Takaori-Kondo, Akifumi




© The Author(s). 2019. This article is distributed under the
terms of the Creative Commons Attribution 4.0 International
License (http://creativecommons.org/licenses/by/4.0/), which
permits unrestricted use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original
author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The
Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to




RESEARCH ARTICLE Open Access
Effect of laminar air flow and building
construction on aspergillosis in acute
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study
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Abstract
Background: The preventive effect of laminar air flow (LAF) on aspergillosis has been observed in patients with
hematological malignancies. However, the short follow-up period limits the interpretation of study results.
Methods: To assess the preventive effect of long-term LAF use on aspergillosis in its long-term use, we retrospectively
analyzed 124 acute leukemia patients at our hospital between January 2005 and March 2016. We compared the
incidence of aspergillosis before (May 2008) and during the construction of a new building (June 2008–January
2010) and in the early (February 2010–March 2014) and late (April 2014–March 2016) periods after moving to a
new hematology ward with an LAF system. The 2008 European Organization for Research and Treatment of
Cancer and Mycosis Study Group criteria were used for the diagnosis of aspergillosis.
Results: Fourteen patients were diagnosed with possible, probable, or definite aspergillosis. Cumulative incidence rates
of aspergillosis at day 180 were 12.4, 24.9, 9.3, and 25.1% before construction, during construction, in the early period after
moving to a new ward, and in the late period after moving to a new ward, respectively (p = 0.106). Multivariate analysis
showed that the LAF system tended to reduce the risk of aspergillosis in the early period (before construction vs. early
period; hazards ratio (HR) = 1.97, p = 0.463 and during construction vs. early period;HR = 3.42, p = 0.184), but the risk
increased in the late period (late vs. early period, HR = 5.65, p= 0.035).
Conclusions: Building construction might increase the risk of aspergillosis. Short-term LAF use might reduce aspergillosis
risk, but its long-term use is inadequate, although we could not exclude the possibility of increased risks in the recent
period due to continued improvements in the different areas of our hospital. Strict maintenance, more effective LAF
system, and optimization of aspergillosis prophylaxis may be necessary.
Keywords: Aspergillosis, Acute leukemia, Laminar air flow, Prevention, Fungal infection
Background
Although the fungal disease-related mortality rate in
acute leukemia patients has decreased with the develop-
ment of effective antifungal drugs and early intervention,
mortality remains high [1, 2]. Exposure to fungi during
the pre-hospitalization and hospitalization period is an
important risk factor for fungal infection [2, 3]. There-
fore, avoidance of fungal exposure is essential, and one
of the effective procedures used to prevent fungal infec-
tion, especially mold infections such as invasive
aspergillosis, is laminar air flow (LAF) isolation. Building
construction or demolition of an adjacent ward area was
reported to be associated with an increase in fungal
spores in the ward and to be one of the important risk
factors for outbreaks of invasive aspergillosis [3, 4]. LAF
systems have been reported to be effective in the preven-
tion of invasive aspergillosis; they are also reported to be
cost-effective [3–5]. Although these reports showed the
effectiveness of LAF in the early period after the
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construction of wards, the long-term preventive effect of
LAF isolation has not been assessed sufficiently. There-
fore, in the present study, we aimed to conduct a retro-
spective analysis of the incidence of invasive aspergillosis
in newly diagnosed acute leukemia patients treated in
our hospital and assess the preventive effect of
long-term LAF isolation against invasive aspergillosis.
Methods
Data collection
We included patients who were newly diagnosed with
acute leukemia and hospitalized in the Hematology and
Oncology department of the Kyoto University Hospital
and who received a series of induction and consolidation
chemotherapies between January 2005 and March 2016.
We excluded patients for whom data on survival status,
treatment regimen, antifungal prophylaxis, and infection
status were lacking; those who had already been diag-
nosed with invasive fungal disease; those who had
received antifungal treatment on initiation of chemo-
therapy; and those who did not receive intensive treat-
ment, i.e. those who received supportive care or
reduced-intensity chemotherapy. A total of 124 acute
leukemia patients were included in this study.
Isolation strategies
In the period before and during construction, all the
patients were treated in a ward without an LAF system.
In the period after moving, all patients were treated in a
ward with an LAF system. In line with the International
Organization for Standardization (ISO) 14,644–1; 2015
classification, we periodically examined the cleanliness
of the ward to confirm that all the ward areas conformed
to ISO 7–8 (class 10,000–100,000 in clean room classifi-
cation according to US guidelines) and the inpatient
rooms conformed to ISO 6 (class 1000, for induction
chemotherapy) or ISO 7 (class 10,000, for consolidation
chemotherapy). We encouraged patients to rehabilitate
outside their rooms even if they had neutropenia, and if
the absolute neutrophil count was > 200 cells/mm3 for 2
days, the patient was permitted to go outside the ward
in the period after moving to an LAF-containing ward.
Prophylaxis of fungal infection
Fluconazole was used as first-line antifungal prophylaxis
for induction and consolidation chemotherapy of acute
leukemia. If patients could not receive drugs orally,
micafungin was used as an alternative prophylactic
agent. When the LAF system malfunctioned in January
2013, micafungin was used as the first-line prophylactic
agent to prevent aspergillosis until July 2013. In two
patients, itraconazole was used for prophylaxis as
ordered by the attending physician. In some cases,
empirical therapy with mould-active antifungal agent,
such as echinocandins, voriconazole, or amphotericin B
was required for treating antibiotic-resistant febrile neu-
tropenia. Empirical use of antifungal drugs without diag-
nosis of fungal infection was considered for preventive
use.
Endpoints
The primary endpoint of this study was the incidence
of aspergillosis. We compared the incidence of asper-
gillosis before (May 2008, phase A) and during the
construction of a new building (June 2008–January
2010, phase B) and in the early (February 2010–
March 2014, phase C) and late period (April 2014–
March 2016, phase D) after moving to the new
hematology ward with an LAF system. The other end-
point that we assessed was the overall incidence of
fungal infection. The 2008 European Organization for
Research and Treatment of Cancer and Mycosis Study
Group criteria (EORTC/MSG 2008 criteria) were used
for the diagnosis of aspergillosis. Without microbio-
logical or histopathological findings, patients were di-
agnosed with aspergillosis when lung involvement was
detected on radiographical examinations, such as
computed tomography, and patients with findings
suggestive of fungal infections other than lung in-
volvement and those who had no microbiological and
histopathological findings were diagnosed with fungal
infection, but not with aspergillosis. The day of diag-
nosis was defined as the day when the criteria for
possible, proven, or probable aspergillosis or fungal
infection were fulfilled.
Statistical analysis
Descriptive statistics were used to summarize patient
characteristics. Comparisons among groups were per-
formed with the Fisher’s exact test for categorical var-
iables and the Kruskal-Wallis test for continuous
variables. The incidence of aspergillosis was estimated
on the basis of cumulative incidence and was com-
pared using the Gray’s test. Competing events were
death without aspergillosis and the incidence of fun-
gal infections other than aspergillosis. Cox propor-
tional hazards ratio was used to evaluate the effect of
the confounding covariates, including time-dependent
covariates. We also performed Fine and Gray propor-
tional hazards regression analysis to consider compet-
ing events but without including time-dependent
covariates.
The following variables were considered in the uni-
variate and multivariate analyses: period of neutro-
penia, lineage of leukemia, age, LAF isolation usage,
and exposure to construction (i.e. comparison
between before construction, during construction, and
the early and late periods after moving to the new
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ward). Period of neutropenia (≤60 vs. > 60 days) was
treated as a time-dependent covariate because the risk
of fungal infection increased with the level of neutro-
penia and repeated chemotherapy. A p value of < 0.05
was used to determine statistical significance.
All statistical analyses were performed with R (the R
Foundation for Statistical Computing, version 3.1.1,
Vienna, Austria) and EZR (Saitama Medical Center, Jichi
Medical University, Saitama, Japan) [6].
Results
Patient characteristics
Patient characteristics are summarized in Table 1. Median
follow-up period was 139 days, and the median age at
diagnosis was 52 years (range, 15–75 years). A total of 72
men and 52 women were included in this study.
In the late period after moving, patients often received
mold-active antifungal agents, such as itraconazole, vori-
conazole, micafungin, caspofungin, amphotericin B, and
liposomal amphotericin B; in the construction period,
patients who often received only fluconazole for preven-
tion; however, the difference between the two groups
was not statistically significant. Although we used mica-
fungin as the first-line prophylaxis due to trouble in LAF
system functioning during a certain period that fell
within the early period after moving, usage of
mold-active agenst did not increase in that period.
Details about acute leukemia subtypes and treatment
strategies are summarised in Table 2. More number of
patients were treated using intensive high-dose cytara-
bine based regimens was higher in the period before
construction than in the other periods. All eight patients
with Philadelphia chromosome positive acute
Table 1 Patient characteristics
Characteristics whole period phase A phase B phase C phase D p value
sex
female 52 16 12 17 7 0.059
male 72 20 6 26 20
age (years) 15–75 (52.0) 25–73 (56.5) 19–71 (46.5) 18–75 (51) 15–70 (52) 0.763
>median(53–75) 59 19 8 19 13 0.890
<median(15–52) 65 17 10 24 14
neutropenia (days) 12–179 (61) 15–150 (65.5) 12–168 (57.0) 18–122 (58.0) 12–179 (53.0) 0.520
>median(62–179) 60 22 8 19 11 0.342
<median(12–61) 64 14 10 24 16
lineage
AML 102 31 15 33 23 0.729
ALL 22 5 3 10 4
prophylaxis
FLCZ only 69 22 14 22 11 0.082
mold-active agent 55 14 4 21 16
ITCZ 6 3 0 1 2
VRCZ 5 1 1 1 2
MCFG 50 12 3 21 14
CPFG 1 0 0 0 1
AMB 1 1 0 0 0
L-AMB 5 0 1 3 1
treatment response after induction
chemotherapy
CR 76 21 11 24 20 0.677
CRi 3 1 1 1 0
non-CR 45 14 6 18 7
median follow-up of event free
survivors (days)
139.0 (27–330) 132.5 (29–236) 149.0 (27–330) 139.0 (42–261) 135.0 (41–272) 0.963
Note. AML denotes acute myelogenous leukemia; ALL acute lymphoblastic leukemia, FLCZ fluconazole, ITCZ itraconazole, VRCZ voriconazole, MCFG micafungin,
CPFG caspofungin, AMB amphotericin b, L-AMB liposomal amphotericin b, CR complete remission, CRi complete remission with incomplete hematologic recovery
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lymphoblastic leukemia or chronic myeloid leukemia
were treated by chemotherapy with tyrosine kinase
inhibitors such as imatinib or dasatinib. Of the six
patients with T-cell acute lymphoblastic leukemia after
moving (Phase C or D), four patients were treated with
nelarabine containing regimens; the other two patients
with early T-cell precursor acute lymphoblastic leukemia
were treated with standard-dose cytarabine and
anthracycline.
The incidence of fungal infection
Twenty patients were diagnosed with possible, probable,
or definite fungal infection (Table 3). However, two
patients could not be diagnosed with fungal infection ac-
cording to the EORTC 2008 criteria; however, one of the
two patients had exudative plaques in the fundus, sug-
gesting candidiasis, and the other patients did not show
positive radiographical, microbiological or histopatho-
logical findings of fungal infection but had prolonged
Table 2 Description about leukemia subtypes and treatment strategies
Characteristics whole period phase A phase B phase C phase D p value
AML subtype
de novo AML 49 13 6 17 13 0.646
AML-MRC 33 13 5 8 7
t-MN 11 3 1 6 1
APL 5 1 2 1 1
CML-BC 1 1 0 0 0
ALL subtype
B-ALL 10 4 0 6 0 0.092
T-ALL 8 0 2 3 3
CML-BC 3 0 1 1 1
induction treatment for AML
SDAC with anthracyclinea 86 21 11 31 20 0.002
HDAC based treatmentsa 11 9 1 0 1
anthracycline with ATRA 5 1 2 1 1
induction treatment for ALL
HyperCVAD-MA 17 5 4 8 0 0.002
other treatments 5 0 0 3 5
AML denotes acute myelogenous leukemia; AML-MRC AML with myeloid dysplasia related changes, t-MN treatment related myeloid neoplasia; APL acute
promyelocytic leukemia, CML-BC chronic myeloid leukemia blast crisis, ALL acute lymphoblastic leukemia, Ph-ALL Philadelphia chromosome positive ALL, B-ALL B
cell ALL, T-ALL T cell ALL, SDAC standard-dose cytarabine, HDAC high-dose cytarabine, ATRA all-trans retinoic acid, HyperCVAD-MA hyperfractionated
cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate, and cytarabine aSDAC means 100-200mg/ m2 of
cytarabine and HDAC means more than 1-2g/ m2 of cytarabine
Table 3 Incidence of fungal infection
Characteristics whole period phase A phase B phase C phase D p value
fungal infection 22 (17.7%) 4 (11.1%) 4 (22.2%) 4 (9.3%) 10 (37.0%) 0.022
none 102 32 14 39 17
possible 14 3 3 4 4
probable 4 0 1 0 3
proven 2 1 0 0 1
suspect ofa 2 0 0 0 2
aspergillosis 14 (11.3%) 3 (8.3%) 3 (16.7%) 2 (4.7%) 6 (22.2%) 0.103
none 110 33 15 41 21
possible 10 3 2 2 3
probable 4 0 1 0 3
aTwo patients could not be diagnosed with fungal infection according to the EORTC 2008 criteria but had clinical findings that were highly suggestive of
fungal infection
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febrile neutropenia with continuously increasing
β-d-glucan values. As a result, 22 patients (17.7% of the
participants) were included in the fungal infection group.
The cumulative incidence rates of fungal infection at day
180 were 15.1, 32.9, 14.4, and 43.3%, in phase A, B, C,
and D, respectively (Fig. 1, Gray test, p = 0.014). Multi-
variate analysis showed that the risk increased signifi-
cantly in the late period after moving (phase D vs. phase
C; hazard ratio (HR) = 4.63, p = 0.010) (Table 4).
Fine-Gray proportional hazards regression for competing
events showed significantly higher risk in the late period
than in the early period after moving (phase D vs. phase
C; HR = 4.64, p = 0.0083) (Table 4).
Incidence of aspergillosis
Fourteen patients (11.3% of the participants) were diag-
nosed with possible, probable, or definite aspergillosis
according to the EORTC/MSG 2008 criteria (Table 3).
As shown in Fig. 1, the cumulative incidence rates of as-
pergillosis at day 180 were 12.4, 24.9, 9.3, and 25.1% in
phase A, B, C, and D, respectively (Fig. 2, Gray test, p =
0.106). Multivariate analysis with time-dependent covari-
ates showed that use of LAF systems tended to reduce
the risk of aspergillosis in the early period (phase A vs.
phase C; HR 1.97, p = 0.463 and and phase B vs. phase
C;HR = 3.42, p = 0.184), but that the risk was increased
in the late period after moving (phase D vs. phase C;
HR = 5.65, p = 0.035) (Table 5). Fine-Gray proportional
hazards regression for competing events showed the
same increasing tendency in the late period after moving
(phase D vs. phase C; HR = 5.28, p = 0.030) (Table 5).
Discussion
Fungal infection is a serious complication in patients
with hematological malignancies who are severely
immunocompromised in its nature and by intensive
treatment, such as chemotherapy or hematopoietic stem
cell transplantation (HSCT) [1, 2]. Some fungi are
spread through air transmission, and the most common
airborne fungus in immunocompromised hosts is asper-
gillus. Environmental control is very essential in the pre-
venting infections caused by airborne fungi, like
aspergillosis and a widely used prevention method is use
of the LAF isolation system.
The LAF system is generally used for protective isola-
tion of immunocompromised patients, especially those
with hematological malignancies receiving intensive
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Fig. 1 Cumulative incidence of fungal infection. Cumulative
incidence of fungal infection in phase A (before construction; the solid
line), B (during construction; the long dotted line), C (in the early
period after moving to a new ward; the short dotted line) and D (in
the late period after moving to a new ward; the dashed dotted line)
Table 4 Multivariate analysis on the incidence of fungal infection
variables Adjusted HR
with model 1a





before construction (phase A) 1.32 0.698 1.21 0.790
during construction (phase B) 2.75 0.163 2.82 0.140
the late period after moving (phase D) 4.63 0.010 4.64 0.008
antifungal prophylaxisd 1.40 0.702 1.41 0.430
ALL vs AML 0.59 0.423 0.62 0.470
age 1.19 0.717 1.23 0.660
AML denotes acute myelogenous leukemia; ALL acute lymphoblastic leukemia, HR hazard ratio
aModel 1 is a Cox proportional hazards ratio with time-dependent covariates
bModel 2 is a Fine and Gray proportional hazard regression model
cHR is calculated by comparison of the incidence in each period with in the early period after moving
dHR is the ratio of the incidence in patients who received fluconazole with mold-active agent prophylaxis with the incidence in patients who received
fluconazole-only prophylaxis
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chemotherapy or undergoing HSCT and having pro-
longed neutropenia. Previously, the LAF isolation system
has been shown to be effective in preventing mold fun-
gal infections and a large case series of HSCT-treated
patients suggested that this protective effect against
mold fungal infections could improve treatment-related
mortality (TRM) [7]. By contrast, a recent report showed
that HSCT could still be performed in outpatient set-
tings that had an invasive aspergillosis incidence as low
as that in inpatient settings [8]. This discrepancy is
caused by multiple factors, such as patient background,
treatment strategy, and local environmental factors
(fungi prefer warm and humid climate); thus, we should
reconsider when and how LAF isolation systems can be
used efficiently.
In the present study, we investigated the effectiveness
of the LAF isolation system after long-term use during
the construction period in an adjacent area of the hos-
pital, and we showed that the protective effect of the
LAF isolation system against fungal infection decreased
after long-term use especially with respect to airborne
fungi infections like aspergillosis. This result suggested
that more efforts should be made for establishing pro-
tective isolation systems, including LAF system mainten-
ance and more intensive preventive strategies should
also be developed against fungal infections with
long-term use of LAF.
In terms of protective isolation, construction in the
adjacent ward might have increased aspergillosis inci-
dence in the late period after LAF ward construction.
Many reports showed that construction, renovation,
demolition, and excavation of buildings around the hos-
pital are reported to be an important risk factors for fun-
gal infection, and the most important pathogen in this
setting is aspergillus [2–4, 9, 10]. Previous reports
showed that the LAF systems could overcome aspergil-
losis outbreaks by inhibiting environmental exposure of
fungal spores, but these reports did not investigate the
effectiveness of LAF after long-term use [3, 4, 11].
The Centers for Disease Control and Prevention pro-
vided the Guidelines for Environmental Infection Con-
trol in HealthCare Facilities, which claimed the
importance of maintenance of air handling systems, in-
fection control risk assessment, and isolation from dusty
external areas [12]. However, a detailed standard is
needed for assessment and development of maintenance
strategies with respect to air quality.
Some reports have shown that the risk of fungal infec-
tion can be partially predicted by counting fungal spore
Fig. 2 Cumulative incidence of aspergillosis. Cumulative incidence
of aspergillosis in phase A (before construction; the solid line), B
(during construction; the long dotted line), C (in the early period
after moving to a new ward; the short dotted line) and D (in the
late period after moving to a new ward; the dashed dotted line)
Table 5 Multivariate analysis of the incidence of aspergillosis
variables Adjusted HR with model 1a p value Adjusted HR with model 2b p value
Neutropenia 0.45 0.362
treatment periodc
before construction (phase A) 1.97 0.463 1.76 0.540
during construction (phase B) 3.42 0.184 3.60 0.170
the late period after moving (phase D) 5.65 0.035 5.28 0.030
antifungal prophylaxisd 0.88 0.818 0.82 0.800
ALL vs AML 0.46 0.348 0.56 0.480
age 0.81 0.709 0.86 0.690
AML denotes acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; HR, hazard ratio
aModel 1 is a Cox proportional hazards ratio model with time-dependent covariates
bModel 2 is a Fine and Gray proportional hazard regression model
cHR is calculated by comparison of the incidence in each period with in the early period after moving
dHR is the ratio of the incidence in patients who received fluconazole with mold-active agent prophylaxis with the incidence in patients who received
fluconazole-only prophylaxis
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colony-forming units [4, 10]. Although the ward area’s
conformance to the ISO criteria was checked, aspergillus
spores are 3–10 μm in diameter. Hence, some patho-
genic spores might have existed especially outside the
rooms in the ward area during the construction of the
adjacent ward.
A recent report showed that environmental control
measures other than LAF isolation systems, during con-
struction were effective in preventing invasive aspergil-
losis [13]. These environmental control measures
include dust control procedures and barriers during con-
struction, and education of healthcare workers regarding
the dangers of nosocomial invasive aspergillosis. We
should reconsider these simple and fundamental
approaches for maintaining hygiene even under LAF iso-
lation settings and for development of maintenance pro-
cedures for wards with the LAF isolation systems.
We should also reconsider the times at which patients
are permitted to go outside the rooms or the ward. Pro-
longed neutropenia is an important risk factor of fungal
infections, but environmental control strategies accord-
ing to neutrophil counts usually vary with each institu-
tion. The SEIFEM 2008 registry study showed that
neutrophil count was usually below 500 cells/mm3 at the
onset of aspergillosis [1]. Hence, the threshold of neutro-
phil count should be defined; patients with neutrophil
counts above this threshold value are safe go outside the
ward with respect to airborne infections, including
aspergillosis. A previous report showed that introduction
of high-efficiency filtration masks that filter particles
sized 0.1 μm prevented aspergillosis efficiently in neutro-
penic patients when they went outside the ward with
LAF isolation [14]. Introduction of high-efficiency fil-
tration masks to neutropenic patients when they go
outside the ward with LAF isolation or even when
they go outside their rooms to rehabilitate might be a
promising strategy.
From the view point of the preventive strategy other
than air quality maintenance, some mold-active antifun-
gal agents could prevent fungal infection, but it is still
controversial whether these agents should be introduced
as prophylactic treatments [15–17]. A previous study
reported that posaconazole was superior to fluconazole
and itraconazole in the incidence of fungal infection and
its mortality at day 100 after hematopoietic stem cell
transplantation. Another report showed that voricona-
zole and caspofungin are promising agents for prevent-
ing aspergillosis during the construction of the areas
adjacent to the ward [15]. However, the superiority of
voriconazole to fluconazole has not been proven in the
previous randomized controlled trials [16]. Because this
study was conducted in 35 centers, heterogeneity in en-
vironmental exposure may be observed. Hence, the rec-
ommended antifungal agents for patients who are highly
exposed to environmental factors, such as construction,
renovation, and long-term use of the LAF systems after
its introduction, should be further studied.
Our study had some limitations, including the small
study cohort and non-randomized and retrospective
study design. Currently, the LAF isolation system is used
for the prevention of mold infection to such an extent
that randomized-controlled study design is not prag-
matic due to ethical considerations. In this study, we
used EORTC/MSG 2008 criteria for diagnosis of fungal
infection in this study, but we also included two patients
who were highly suspected of fungal infection by the at-
tending physicians without being diagnosed according to
these criteria. Biopsies are needed for proving fungal in-
fections but are often not feasible because of the
high-risk of complications. Serum markers, such as
β-d-glucan value, are often used but the usefulness of
these markers is still controversial [18]. Prophylaxis for
fungal infection is also influenced by the decisions of the
attending physicians. As per our hospital policy, we used
fluconazole as the first-line prophylactic agent for fungal
infection during the treatment of acute leukemia, but
some patients were prescribed mold-active agents, such
as itraconazole, voriconazole, echinocandins, and
amphotericin B. Prospective study design might be pref-
erable for standardizing the criteria for diagnosis and
prophylaxis of fungal infections.
Conclusions
We found that the preventive effect of the LAF isolation
system declined with long-term use. We should recon-
sider and establish the maintenance and assessment pro-
cedures of air quality in the ward, appropriate isolation
strategies of immunocompromised patients, and fungal
infection prophylaxis, especially in patients who are
highly exposed to environmental factors.
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